Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 3;12(1):161.
doi: 10.1186/s13287-021-02212-0.

Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities

Yun-Xing Fu  1 , Jing Ji  1 , Fang Shan  1 , Jialing Li  1 , Rong Hu  2
Affiliations
Review

Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities

Yun-Xing Fu et al. Stem Cell Res Ther. .

Abstract

Premature ovarian failure (POF) is one of the common disorders found in women leading to 1% female infertility. Clinical features of POF are hypoestrogenism or estrogen deficiency, increased gonadotropin level, and, most importantly, amenorrhea. With the development of regenerative medicine, human mesenchymal stem cell (hMSC) therapy brings new prospects for POF. This study aimed to describe the types of MSCs currently available for POF therapy, their biological characteristics, and their mechanism of action. It reviewed the latest findings on POF to provide the theoretical basis for further investigation and clinical therapy.

Keywords: Mesenchymal stem cells; Ovarian function; Premature ovarian failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Effects and mechanisms of hBMMSCs on POF
Fig. 2
Fig. 2
Effects and mechanisms of hPMSCs on POF
Fig. 3
Fig. 3
Effects and mechanisms of hAMSCs on POF
Fig. 4
Fig. 4
Effects and mechanisms of hAFMSCs on POF
Fig. 5
Fig. 5
Effects and mechanisms of hMB-MSCs on POF
Fig. 6
Fig. 6
Effects and mechanisms of hADMSCs on POF
Fig. 7
Fig. 7
Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities
See this image and copyright information in PMC

References

    1. Coulam CB. Premature gonadal failure. Fertil Steril. 1982;38(6):645–655. doi: 10.1016/S0015-0282(16)46688-4. - DOI - PubMed
    1. Pastore LM, Christianson MS, Stelling J, et al. Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR. J Assist Reprod Genet. 2018;35(1):17–23. doi: 10.1007/s10815-017-1058-4. - DOI - PMC - PubMed
    1. Orlandini C, Regini C, Vellucci FL, Petraglia F, Luisi S. Genes involved in the pathogenesis of premature ovarian insufficiency. Minerva Ginecol. 2015;67(5):421–430. - PubMed
    1. Ebrahimi M, Asbagh FA. The role of autoimmunity in premature ovarian failure. Iran J Reprod Med. 2015;13(8):461. - PMC - PubMed
    1. Yan G, Schoenfeld D, Penney C, Hurxthal K, Taylor AE, Faustman D. Identification of premature ovarian failure patients with underlying autoimmunity. J Womens Health Gend Based Med. 2000;9(3):275–287. doi: 10.1089/152460900318461. - DOI - PubMed

Publication types

Substances